STSS_OUT_1 [2025-04-17 10:25:33 -0400] 4673 Bytes | 1245 tokens | Cum: 1245 tkns (15.56% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Sharps Technology (STSS) which is at 0.0352 up from 0.0265. So, I pulled together a bunch of data for you to look over real fast. It's still early, 10:25:33 AM on Thu Apr 17, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Sharps Technology (STSS)
IPO: 2022-04-14 (3 Years Ago)
Market Cap: $302,429
Shares Outstanding: 11,080,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.

Here’s a list of headlines for Sharps Technology:

Mar-20-25 07:00AM - Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025
Mar-06-25 07:00AM - Sharps Technology's CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary
Jan-29-25 10:45AM - Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering
Jan-28-25 09:00AM - Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering
Dec-05-24 10:00AM - Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue
Dec-05-24 10:00AM 08:30AM - Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Nov-18-24 08:00AM - Sharps Regains Nasdaq Listing Compliance
Oct-14-24 08:00AM - Sharps Technology, Inc. Announces Stockholders' Approval of Reverse Stock Split Ratio and Effective Date

Prior AI Reports for STSS:
1. 2025-04-02 – Score: 10 – Target: 0.0313 – Highs: 0.0334 / 0.0293 / 0.03
companys-troubling-financial-state-signals-potential-downturn
2. 2025-04-01 – Score: 5 – Target: 0.0364 – Highs: 0.0369 / 0.0334 / 0.03
companys-financial-health-in-jeopardy-amidst-severe-negative-performance

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-06T12:00:00Z - Sharps Technology’s CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary
B2 - 2024-12-05T15:00:00Z - Sharps Technology’s CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue
B3 - 2024-09-23T10:00:00Z - Sharps Technology, Inc. Announces $3.5 Million Bridge Financing
B4 - 2024-07-05T19:35:54Z - Gold Gains Over 1%; NIO Shares Slide - Koss (NASDAQ:KOSS) - Benzinga
B5 - 2024-07-05T09:42:31Z - Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket - Sharps ... - Benzinga
B6 - 2024-07-03T17:06:17Z - Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery - GlobeNewswire

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Sharps Technology (STSS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

STSS_OUT_3 [2025-04-17 10:25:36 -0400] 1026 Bytes | 249 tokens | Cum: 1496 tkns (18.70% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Sharps Technology’s CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/06/3038057/0/en/Sharps-Technology-s-CEO-Issues-Corporate-Update-Highlighting-Agreements-for-SecureGard-and-SoloGard-and-Revenue-Developments-from-Manufacturing-Operations-in-Hungary.htmlSharps Technology secures $20 million in financing, advancing manufacturing capabilities in Hungary to accelerate shipments under existing agreements for SecureGard and SoloGard products. The company is well-positioned to capitalize on growing demand for innovative injection solutions.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_5 [2025-04-17 10:25:37 -0400] 1039 Bytes | 305 tokens | Cum: 1803 tkns (22.54% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T12:09:34Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Forian (NASDAQ:FORA), Channel Therap...
A2 - 2025-04-17T08:59:35Z - Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Asure Soft...
A3 - 2025-04-15T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Apt...
A4 - 2025-04-14T17:05:56Z - 12 Health Care Stocks Moving In Monday's Intraday Session - Applied DNA Sciences (NASDAQ:APDN), Alum...
A5 - 2025-04-14T12:08:48Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Gyre Therapeutics (NASDAQ:GYRE), Artel...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

STSS_OUT_7 [2025-04-17 10:25:40 -0400] 1181 Bytes | 348 tokens | Cum: 2153 tkns (26.91% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Forian (NASDAQ:FORA), Channel Therapeutics (AMEX:CHRO)**Date: 2025-04-17Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44861498/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers Channel Therapeutics CHRO stock increased by 86.5% to $2.34 during Thursday's pre-market session. The market value of their outstanding shares is at $14.1 million. Sharps Technology STSS stock rose 34.33% to $0.04. InnovAge Holding INNV stock increased by 19.71% to $3.4. The market value of their outstanding shares is at $459.8 million. Quoin Pharmaceuticals QNRX stock increased by 19.35% to $7.16. The market value of their outstanding shares is at $147.4 million. Sunshine Biopharma SBFM shares rose 14.75% to $1.4. The market value of their outstandin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_9 [2025-04-17 10:25:40 -0400] 1181 Bytes | 345 tokens | Cum: 2500 tkns (31.25% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): g shares is at $5.0 million. China SXT Pharmaceuticals SXTC shares rose 14.25% to $1.13. The company's market cap stands at $15.5 million. Losers Forian FORA shares fell 36.0% to $1.26 during Thursday's pre-market session. The market value of their outstanding shares is at $39.3 million. TNF Pharmaceuticals TNFA shares decreased by 23.9% to $0.19. As per the news, the Q4 earnings report came out 4 days ago. Sophia Genetics SOPH stock declined by 19.58% to $2.26. The company's market cap stands at $150.1 million. UnitedHealth Group UNH stock declined by 19.33% to $472.0. The company's market cap stands at $431.7 billion. As per the press release, Q1 earnings came out today. Tourmaline Bio TRML shares declined by 15.98% to $12.2. The company's market cap stands at $313.3 million. enVVeno Medical NVNO shares declined by 15.13% to $2.02. The company's market cap stands at $35.4 million. See

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_11 [2025-04-17 10:25:41 -0400] 1097 Bytes | 353 tokens | Cum: 2855 tkns (35.69% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHROChannel Therapeutics Corp$2.3788.8%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum73.30Price TrendShortMediumLongOverviewFORAForian Inc$1.25-36.5%INNVInnovAge Holding Corp$3.2012.7%NVNOenVVeno Medical Corp$2.02-15.1%QNRXQuoin Pharmaceuticals Ltd$6.6811.3%SBFMSunshine Biopharma Inc$1.230.82%SOPHSophia Genetics SA$2.25-19.9%STSSSharps Technology Inc$0.036537.7%SXTCChina SXT Pharmaceuticals Inc$1.1011.2%TNFATNF Pharmaceuticals Inc$0.1936-21.2%TRMLTourmaline Bio Inc$12.20-16.0%UNHUnitedHealth Group Inc$473.00-19.1%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_13 [2025-04-17 10:25:42 -0400] 1055 Bytes | 233 tokens | Cum: 3090 tkns (38.62% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis summarizes the significant factors affecting the CONS operating results, financial condition, liquidity and cash flows of our Company as o...

S3 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis summarizes the significant factors affecting the CONS operating results, financial condition, liquidity and cash flows of our Company as o...

S4 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis summarizes the significant factors affecting the CONS operating results, financial condition, liquidity and cash flows of our Company as o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

STSS_OUT_15 [2025-04-17 10:25:43 -0400] 1181 Bytes | 255 tokens | Cum: 3347 tkns (41.84% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of our Company as of and for the periods presented below. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and notes included in this Annual Report on Form 10-K as of and for the years ended December 31, 2024 and 2023. Unless the context requires otherwise, references in this Annual Report on Form 10-K to we, us, and our refer to Sharps Technology, Inc.

##TABLE_START 20 ##TABLE_END

Forward-Looking Statements

The information in this discussion contains forward-looking statements and information within the meaning of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_17 [2025-04-17 10:25:46 -0400] 1181 Bytes | 254 tokens | Cum: 3603 tkns (45.04% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words anticipates, believes, estimates, expects, intends, may, plans, projects, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. A

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_19 [2025-04-17 10:25:47 -0400] 1181 Bytes | 250 tokens | Cum: 3855 tkns (48.19% of 8k)
==========================================================================

Showing S2 (chunk 3 of 6): ctual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements .

Overview

Since our inception in 2017 and through the fourth quarter of 2022, we have devoted substantially all of our resources to the research and development of our safety syringe products Commencing in the fourth quarter of 2022 we started building inventory of syringe products. To date, we have generated no revenue. We have

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_21 [2025-04-17 10:25:48 -0400] 1181 Bytes | 262 tokens | Cum: 4119 tkns (51.49% of 8k)
==========================================================================

Showing S2 (chunk 4 of 6): incurred net losses of $9,296,202 and $9,841,638 for the years ended December 31, 2024 and 2023, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development efforts, payroll and consulting fees, stock compensation and general and administrative costs associated with our operations, including costs incurred for being a public company since April 14, 2022. See below Initial Public Offering, Liquidity and Capital Resources and Notes to Consolidated Financial Statements

We classify our operating expenses as research and development, and general and administrative expenses. We maintain a corporate office located in Melville, New York, but employees and consultants in the US work remotely and will continue to do so indefinitely. In June 2020, in connection with the agreement to acquire Safegard, a syringe manufacturing facil

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_23 [2025-04-17 10:25:49 -0400] 1181 Bytes | 251 tokens | Cum: 4372 tkns (54.65% of 8k)
==========================================================================

Showing S2 (chunk 5 of 6): ity in Hungary, which was completed on July 6, 2022, we were contractually provided the exclusive use of the facility for research and development and testing in exchange for payment of the sellers operating costs, including among others, use of Safegards work force, utility costs and other services.

To remain competitive, we must build inventory. We began this process in the 4 th Quarter of 2022. To secure orders we require commercial quantities of inventory with delivery expected shortly after ordwer are.

Research and Development

Research and development expense consists of expenses incurred while performing research and development activities for our various syringe products. We recognize research and development expenses as they are incurred Substantially all of our research and development expenses to date have been incurred in connection with our syringe products. We expect o

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_25 [2025-04-17 10:25:50 -0400] 790 Bytes | 192 tokens | Cum: 4566 tkns (57.07% of 8k)
==========================================================================

Showing S2 (chunk 6 of 6): ur research and development expenses to increase for the foreseeable future as we continue to enhance our products to meet the market requirements for our Sharps syringe product line for its various intended uses throughout the world.

##TABLE_START 21 ##TABLE_END

Initial Public Offering

On April 13, 2022, our registration statement on Form S-1 (File No. 333-263715), as amended, related to our IPO was declared effective by the SEC, and our common stock and warrants began trading on the Nasdaq Ca...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

STSS_OUT_27 [2025-04-17 10:25:59 -0400] 6109 Bytes | 1603 tokens | Cum: 6171 tkns (77.14% of 8k)
==========================================================================

This is our set of metrics for Sharps Technology.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+--------------------------+
| Volume: 271,838,608 | Perf Month: -89.44% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+--------------------------+
| Avg Volume: 92.19M | Perf Quarter: -98.21% | Short Float: 42.65% | ROE: -187.23% |
+---------------------+-----------------------+------------------------+--------------------------+
| Rel Volume: 20.00 | Index: - | Short Ratio: 0.07 | ROI: -465.71% |
+---------------------+-----------------------+------------------------+--------------------------+
| RSI (14): 31.55 | Market Cap: 0.55M | Short Interest: 6.35M | Sales Surprise: -100.00% |
+---------------------+-----------------------+------------------------+--------------------------+
| ATR (14): 0.04 | Shs Outstand: 16.33M | Beta: 1.97 | EPS Surprise: -175.00% |
+---------------------+-----------------------+------------------------+--------------------------+
| SMA20: -47.50% | Shs Float: 14.88M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+--------------------------+
| SMA50: -85.20% | Inst Own: 3.28% | Sales past 5Y: 0.00% | Earnings: - |
+---------------------+-----------------------+------------------------+--------------------------+
| SMA200: -98.81% | Insider Own: 8.89% | Employees: 55 | |
+---------------------+-----------------------+------------------------+--------------------------+
| Perf Week: 83.61% | Insider Trans: 26.54% | Debt/Eq: 1.88 | |
+---------------------+-----------------------+------------------------+--------------------------+

The next section covers any insider trading by Sharps Technology officers or majority shareholders (if available).

Inside Trans: Sharps Technology Inc. (STSS) by Hayes Robert Michael (Chief Executive Officer) on 2025-02-28
- Common Stock: 175000 shares at $0.04 (D)
- Common Stock: 125000 shares at $0.03 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9296202.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.0352
Average Volume: 220944691.96
30-Day High: 0.346
30-Day Low: 0.014

[Detailed Financials: TTM 2024]
- Total Assets: $7,313,748.0
- Total Liabilities: $5,317,619.0
- Total Equity: $1,996,129.0
- Current Assets: $3,173,940.0
- Current Liabilities: $5,185,619.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.4

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-2,185,274.0

[Detailed Financials: FY 2024]
- Total Assets: $7,313,748.0
- Total Liabilities: $5,317,619.0
- Total Equity: $1,996,129.0
- Current Assets: $3,173,940.0
- Current Liabilities: $5,185,619.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.4

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-2,185,274.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Sharps Technology (STSS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Sharps Technology.

2) MARKET_SCORE[]
This conversation was initiated because STSS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for STSS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, STSS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect STSS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Sharps Technology.

11) ETHICAL_RATING[]
Rate Sharps Technology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Sharps Technology.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

STSS_IN_29 [2025-04-17 10:25:59 -0400] 126 Bytes | 29 tokens | Cum: 6404 tkns (80.05% of 8k)
==========================================================================

====================================
[2025-04-17 10:25:59] # Analysis Completed
Elapsed Time: 26.54 seconds